Recombinant yeast as an antifungal vaccine

November 28, 2000

Despite the long and successful history of vaccine use, primarily for viral diseases, fungal pathogens have only rarely been considered as targets for vaccination. To date, only one antifungal vaccine, designed to prevent ringworm in cattle, has progressed beyond the experimental stage. Wüthrich et al. now describe the use of a live attenuated strain of Blastomyces dermatitidis to prevent blastomycosis, an often-fatal yeast infection of the lung. Mice immunized with killed wild-type B. dermatitidis mount an immune response to one of its major cell surface adhesion proteins, WI-1, but they are only weakly protected when challenged with the live pathogen. Wüthrich and coworkers previously took advantage of the tractable genetics of this yeast to create a strain lacking the WI-1 gene, showing that this strain could not propagate or cause disease in mice Here, they report that live WI-1- yeast provoke a T cell response that protects inoculated animals from infection with wild-type B. dermatitidis. Crucially, this protection applies not only against yeast that are isogenic to the attenuated strain, but also to several unrelated pathogenic isolates. The authors also show that fungal cell wall preparations derived from the WI-1- strain also protect mice from lung infections, raising the possibility that, as with the live attenuated organism, one or more purified fungal components could be used as an effective vaccine.

JCI Journals

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to